Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

The FNIH Biomarkers Consortium embraces the BEST.

Menetski JP, Austin CP, Brady LS, Eakin G, Leptak C, Meltzer A, Wagner JA.

Nat Rev Drug Discov. 2019 Jul;18(8):567-568. doi: 10.1038/d41573-019-00015-w. No abstract available.

PMID:
31367046
2.

The NCATS BioPlanet - An Integrated Platform for Exploring the Universe of Cellular Signaling Pathways for Toxicology, Systems Biology, and Chemical Genomics.

Huang R, Grishagin I, Wang Y, Zhao T, Greene J, Obenauer JC, Ngan D, Nguyen DT, Guha R, Jadhav A, Southall N, Simeonov A, Austin CP.

Front Pharmacol. 2019 Apr 26;10:445. doi: 10.3389/fphar.2019.00445. eCollection 2019.

3.

International collaborative actions and transparency to understand, diagnose, and develop therapies for rare diseases.

Boycott KM, Lau LP, Cutillo CM, Austin CP.

EMBO Mol Med. 2019 May;11(5). pii: e10486. doi: 10.15252/emmm.201910486. No abstract available.

4.

Mapping biologically active chemical space to accelerate drug discovery.

Sittampalam GS, Rudnicki DD, Tagle DA, Simeonov A, Austin CP.

Nat Rev Drug Discov. 2019 Feb;18(2):83-84. doi: 10.1038/d41573-018-00007-2. No abstract available.

PMID:
30710133
5.

The NIH Blueprint for Neuroscience Research Seeks Community Input on Future Neuroscience Investments.

Mott MC, Austin CP, Bianchi DW, Cashion AK, Gordon JA, Heemskerk JE, Hodes RJ, Koob GF, Riley WT, Sieving PA, Shurtleff D, Somerman MJ, Volkow ND, Anderson KC, Owens DF, Koroshetz WJ.

J Neurosci. 2019 Jan 30;39(5):774-775. doi: 10.1523/JNEUROSCI.2742-18.2018. No abstract available.

6.

The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic Direction.

Menetski JP, Hoffmann SC, Cush SS, Kamphaus TN, Austin CP, Herrling PL, Wagner JA.

Clin Pharmacol Ther. 2019 Apr;105(4):829-843. doi: 10.1002/cpt.1362.

7.

Deconstructing the Translational Tower of Babel.

Austin CP, Colvis CM, Southall NT.

Clin Transl Sci. 2019 Mar;12(2):85. doi: 10.1111/cts.12595. Epub 2018 Nov 9. No abstract available.

8.

Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response.

Nilubol N, Boufraqech M, Zhang L, Gaskins K, Shen M, Zhang YQ, Gara SK, Austin CP, Kebebew E.

Oncotarget. 2018 Aug 31;9(68):33030-33042. doi: 10.18632/oncotarget.26050. eCollection 2018 Aug 31.

9.

Comprehensive Analyses and Prioritization of Tox21 10K Chemicals Affecting Mitochondrial Function by in-Depth Mechanistic Studies.

Xia M, Huang R, Shi Q, Boyd WA, Zhao J, Sun N, Rice JR, Dunlap PE, Hackstadt AJ, Bridge MF, Smith MV, Dai S, Zheng W, Chu PH, Gerhold D, Witt KL, DeVito M, Freedman JH, Austin CP, Houck KA, Thomas RS, Paules RS, Tice RR, Simeonov A.

Environ Health Perspect. 2018 Jul 26;126(7):077010. doi: 10.1289/EHP2589. eCollection 2018 Jul.

10.

Genome editing to 're-write' wrongs.

Perry ME, Valdes KM, Wilder E, Austin CP, Brooks PJ.

Nat Rev Drug Discov. 2018 Oct;17(10):689-690. doi: 10.1038/nrd.2018.91. Epub 2018 Jun 22. No abstract available.

PMID:
29930285
11.

Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery.

Coussens NP, Sittampalam GS, Guha R, Brimacombe K, Grossman A, Chung TDY, Weidner JR, Riss T, Trask OJ, Auld D, Dahlin JL, Devanaryan V, Foley TL, McGee J, Kahl SD, Kales SC, Arkin M, Baell J, Bejcek B, Gal-Edd N, Glicksman M, Haas JV, Iversen PW, Hoeppner M, Lathrop S, Sayers E, Liu H, Trawick B, McVey J, Lemmon VP, Li Z, McManus O, Minor L, Napper A, Wildey MJ, Pacifici R, Chin WW, Xia M, Xu X, Lal-Nag M, Hall MD, Michael S, Inglese J, Simeonov A, Austin CP.

Clin Transl Sci. 2018 Sep;11(5):461-470. doi: 10.1111/cts.12570. Epub 2018 Jul 24. Review.

12.

Recommendations toward a human pathway-based approach to disease research.

Marshall LJ, Austin CP, Casey W, Fitzpatrick SC, Willett C.

Drug Discov Today. 2018 Nov;23(11):1824-1832. doi: 10.1016/j.drudis.2018.05.038. Epub 2018 Jun 2. Review.

13.

Translating translation.

Austin CP.

Nat Rev Drug Discov. 2018 Jul;17(7):455-456. doi: 10.1038/nrd.2018.27. Epub 2018 Apr 20. No abstract available.

14.

Expanding biological space coverage enhances the prediction of drug adverse effects in human using in vitro activity profiles.

Huang R, Xia M, Sakamuru S, Zhao J, Lynch C, Zhao T, Zhu H, Austin CP, Simeonov A.

Sci Rep. 2018 Feb 28;8(1):3783. doi: 10.1038/s41598-018-22046-w.

15.

Application of a Dynamic Map for Learning, Communicating, Navigating, and Improving Therapeutic Development.

Wagner JA, Dahlem AM, Hudson LD, Terry SF, Altman RB, Gilliland CT, DeFeo C, Austin CP.

Clin Transl Sci. 2018 Mar;11(2):166-174. doi: 10.1111/cts.12531. Epub 2017 Dec 22.

16.

A dynamic map for learning, communicating, navigating and improving therapeutic development.

Wagner J, Dahlem AM, Hudson LD, Terry SF, Altman RB, Gilliland CT, DeFeo C, Austin CP.

Nat Rev Drug Discov. 2018 Feb;17(2):150. doi: 10.1038/nrd.2017.217. Epub 2017 Dec 22. No abstract available.

PMID:
29269942
17.

A Global Approach to Rare Diseases Research and Orphan Products Development: The International Rare Diseases Research Consortium (IRDiRC).

Cutillo CM, Austin CP, Groft SC.

Adv Exp Med Biol. 2017;1031:349-369. doi: 10.1007/978-3-319-67144-4_20.

PMID:
29214582
18.

Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework.

Baynam G, Bowman F, Lister K, Walker CE, Pachter N, Goldblatt J, Boycott KM, Gahl WA, Kosaki K, Adachi T, Ishii K, Mahede T, McKenzie F, Townshend S, Slee J, Kiraly-Borri C, Vasudevan A, Hawkins A, Broley S, Schofield L, Verhoef H, Groza T, Zankl A, Robinson PN, Haendel M, Brudno M, Mattick JS, Dinger ME, Roscioli T, Cowley MJ, Olry A, Hanauer M, Alkuraya FS, Taruscio D, Posada de la Paz M, Lochmüller H, Bushby K, Thompson R, Hedley V, Lasko P, Mina K, Beilby J, Tifft C, Davis M, Laing NG, Julkowska D, Le Cam Y, Terry SF, Kaufmann P, Eerola I, Norstedt I, Rath A, Suematsu M, Groft SC, Austin CP, Draghia-Akli R, Weeramanthri TS, Molster C, Dawkins HJS.

Adv Exp Med Biol. 2017;1031:55-94. doi: 10.1007/978-3-319-67144-4_4. Review.

PMID:
29214566
19.

The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact.

Lochmüller H, Torrent I Farnell J, Le Cam Y, Jonker AH, Lau LP, Baynam G, Kaufmann P, Dawkins HJ, Lasko P, Austin CP, Boycott KM; IRDiRC Consortium Assembly.

Eur J Hum Genet. 2017 Dec;25(12):1293-1302. doi: 10.1038/s41431-017-0008-z. Epub 2017 Nov 20.

20.

Voluntary Site Accreditation - Improving the Execution of Multicenter Clinical Trials.

Johnston SC, Austin CP, Lewis-Hall F.

N Engl J Med. 2017 Oct 12;377(15):1414-1415. doi: 10.1056/NEJMp1709203. No abstract available.

PMID:
29020596
21.

Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.

Ory DS, Ottinger EA, Farhat NY, King KA, Jiang X, Weissfeld L, Berry-Kravis E, Davidson CD, Bianconi S, Keener LA, Rao R, Soldatos A, Sidhu R, Walters KA, Xu X, Thurm A, Solomon B, Pavan WJ, Machielse BN, Kao M, Silber SA, McKew JC, Brewer CC, Vite CH, Walkley SU, Austin CP, Porter FD.

Lancet. 2017 Oct 14;390(10104):1758-1768. doi: 10.1016/S0140-6736(17)31465-4. Epub 2017 Aug 10.

22.

Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective.

Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, Julkowska D, Thomson D, Terry SF, de Montleau B, Ardigò D, Hivert V, Boycott KM, Baynam G, Kaufmann P, Taruscio D, Lochmüller H, Suematsu M, Incerti C, Draghia-Akli R, Norstedt I, Wang L, Dawkins HJS; International Rare Diseases Research Consortium (IRDiRC).

Clin Transl Sci. 2018 Jan;11(1):21-27. doi: 10.1111/cts.12500. Epub 2017 Oct 23. Review. No abstract available.

23.

Progress in Rare Diseases Research 2010-2016: An IRDiRC Perspective.

Dawkins HJS, Draghia-Akli R, Lasko P, Lau LPL, Jonker AH, Cutillo CM, Rath A, Boycott KM, Baynam G, Lochmüller H, Kaufmann P, Le Cam Y, Hivert V, Austin CP; International Rare Diseases Research Consortium (IRDiRC).

Clin Transl Sci. 2018 Jan;11(1):11-20. doi: 10.1111/cts.12501. Epub 2017 Oct 23. Review. No abstract available.

24.

Medical research: Next decade's goals for rare diseases.

Austin CP, Dawkins HJS.

Nature. 2017 Aug 9;548(7666):158. doi: 10.1038/548158c. No abstract available.

PMID:
28796211
25.

Methyl-β-cyclodextrin restores impaired autophagy flux in Niemann-Pick C1-deficient cells through activation of AMPK.

Dai S, Dulcey AE, Hu X, Wassif CA, Porter FD, Austin CP, Ory DS, Marugan J, Zheng W.

Autophagy. 2017 Aug 3;13(8):1435-1451. doi: 10.1080/15548627.2017.1329081. Epub 2017 Jun 14.

26.

The importance of international collaboration for rare diseases research: a European perspective.

Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, Jonker AH, Lau LPL, Norstedt I, Rath A, Schuster R, Simelyte E, van Weely S.

Gene Ther. 2017 Sep;24(9):562-571. doi: 10.1038/gt.2017.29. Epub 2017 Jul 27. Review.

27.

Fostering collaborative research for rare genetic disease: the example of niemann-pick type C disease.

Walkley SU, Davidson CD, Jacoby J, Marella PD, Ottinger EA, Austin CP, Porter FD, Vite CH, Ory DS.

Orphanet J Rare Dis. 2016 Dec 1;11(1):161.

28.

'IRDiRC Recognized Resources': a new mechanism to support scientists to conduct efficient, high-quality research for rare diseases.

Lochmüller H, Le Cam Y, Jonker AH, Lau LP, Baynam G, Kaufmann P, Lasko P, Dawkins HJ, Austin CP, Boycott KM.

Eur J Hum Genet. 2017 Feb;25(2):162-165. doi: 10.1038/ejhg.2016.137. Epub 2016 Oct 26.

29.

Putting translational science on to a global stage.

Gilliland CT, Zuk D, Kocis P, Johnson M, Hay S, Hajduch M, Bietrix F, Aversa G, Austin CP, Ussi AE.

Nat Rev Drug Discov. 2016 Apr;15(4):217-8. doi: 10.1038/nrd.2016.33.

30.

Basic science: Bedrock of progress.

Collins FS, Anderson JM, Austin CP, Battey JF, Birnbaum LS, Briggs JP, Clayton JA, Cuthbert B, Eisinger RW, Fauci AS, Gallin JI, Gibbons GH, Glass RI, Gottesman MM, Gray PA, Green ED, Greider FB, Hodes R, Hudson KL, Humphreys B, Katz SI, Koob GF, Koroshetz WJ, Lauer MS, Lorsch JR, Lowy DR, McGowan JJ, Murray DM, Nakamura R, Norris A, Perez-Stable EJ, Pettigrew RI, Riley WT, Rodgers GP, Sieving PA, Somerman MJ, Spong CY, Tabak LA, Volkow ND, Wilder EL.

Science. 2016 Mar 25;351(6280):1405. doi: 10.1126/science.351.6280.1405-a. No abstract available.

31.

Modelling the Tox21 10 K chemical profiles for in vivo toxicity prediction and mechanism characterization.

Huang R, Xia M, Sakamuru S, Zhao J, Shahane SA, Attene-Ramos M, Zhao T, Austin CP, Simeonov A.

Nat Commun. 2016 Jan 26;7:10425. doi: 10.1038/ncomms10425.

32.

Gene Therapy: The View from NCATS.

Brooks PJ, Yang NN, Austin CP.

Hum Gene Ther. 2016 Jan;27(1):7-13. doi: 10.1089/hum.2016.29018.pjb. No abstract available.

33.

Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical Research.

Langley G, Austin CP, Balapure AK, Birnbaum LS, Bucher JR, Fentem J, Fitzpatrick SC, Fowle JR 3rd, Kavlock RJ, Kitano H, Lidbury BA, Muotri AR, Peng SQ, Sakharov D, Seidle T, Trez T, Tonevitsky A, van de Stolpe A, Whelan M, Willett C.

Environ Health Perspect. 2015 Nov;123(11):A268-72. doi: 10.1289/ehp.1510345.

34.

The NIH-Industry New Therapeutic Uses Pilot Program: Demonstrating the Power of Crowdsourcing.

Colvis CM, Austin CP.

Assay Drug Dev Technol. 2015 Jul-Aug;13(6):297-8. doi: 10.1089/adt.2015.29006.cmcdrrr. No abstract available.

35.

Genome-wide Analysis of Host-Plasmodium yoelii Interactions Reveals Regulators of the Type I Interferon Response.

Wu J, Cai B, Sun W, Huang R, Liu X, Lin M, Pattaradilokrat S, Martin S, Qi Y, Nair SC, Bolland S, Cohen JI, Austin CP, Long CA, Myers TG, Wang RF, Su XZ.

Cell Rep. 2015 Jul 28;12(4):661-72. doi: 10.1016/j.celrep.2015.06.058. Epub 2015 Jul 16.

36.

Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays.

Lee JA, Shinn P, Jaken S, Oliver S, Willard FS, Heidler S, Peery RB, Oler J, Chu S, Southall N, Dexheimer TS, Smallwood J, Huang R, Guha R, Jadhav A, Cox K, Austin CP, Simeonov A, Sittampalam GS, Husain S, Franklin N, Wild DJ, Yang JJ, Sutherland JJ, Thomas CJ.

PLoS One. 2015 Jul 15;10(7):e0130796. doi: 10.1371/journal.pone.0130796. eCollection 2015.

37.

Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes.

Schreiber SL, Kotz JD, Li M, Aubé J, Austin CP, Reed JC, Rosen H, White EL, Sklar LA, Lindsley CW, Alexander BR, Bittker JA, Clemons PA, de Souza A, Foley MA, Palmer M, Shamji AF, Wawer MJ, McManus O, Wu M, Zou B, Yu H, Golden JE, Schoenen FJ, Simeonov A, Jadhav A, Jackson MR, Pinkerton AB, Chung TD, Griffin PR, Cravatt BF, Hodder PS, Roush WR, Roberts E, Chung DH, Jonsson CB, Noah JW, Severson WE, Ananthan S, Edwards B, Oprea TI, Conn PJ, Hopkins CR, Wood MR, Stauffer SR, Emmitte KA; NIH Molecular Libraries Project Team.

Cell. 2015 Jun 4;161(6):1252-65. doi: 10.1016/j.cell.2015.05.023. Review.

38.

Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study.

Abdo N, Xia M, Brown CC, Kosyk O, Huang R, Sakamuru S, Zhou YH, Jack JR, Gallins P, Xia K, Li Y, Chiu WA, Motsinger-Reif AA, Austin CP, Tice RR, Rusyn I, Wright FA.

Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.

39.

Profiling of the Tox21 chemical collection for mitochondrial function to identify compounds that acutely decrease mitochondrial membrane potential.

Attene-Ramos MS, Huang R, Michael S, Witt KL, Richard A, Tice RR, Simeonov A, Austin CP, Xia M.

Environ Health Perspect. 2015 Jan;123(1):49-56. doi: 10.1289/ehp.1408642. Epub 2014 Oct 10.

40.

Identification of small molecule modulators of gene transcription with anticancer activity.

Tran TA, Wichterman-Kouznetsova J, Varghese D, Huang R, Huang W, Becker M, Austin CP, Inglese J, Johnson RL, Martinez ED.

ACS Chem Biol. 2014 Nov 21;9(11):2603-11. doi: 10.1021/cb500532x. Epub 2014 Sep 16.

41.

Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway.

Huang R, Sakamuru S, Martin MT, Reif DM, Judson RS, Houck KA, Casey W, Hsieh JH, Shockley KR, Ceger P, Fostel J, Witt KL, Tong W, Rotroff DM, Zhao T, Shinn P, Simeonov A, Dix DJ, Austin CP, Kavlock RJ, Tice RR, Xia M.

Sci Rep. 2014 Jul 11;4:5664. doi: 10.1038/srep05664.

42.

Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy.

Yu D, Swaroop M, Wang M, Baxa U, Yang R, Yan Y, Coksaygan T, DeTolla L, Marugan JJ, Austin CP, McKew JC, Gong DW, Zheng W.

J Biomol Screen. 2014 Sep;19(8):1164-73. doi: 10.1177/1087057114537378. Epub 2014 Jun 6.

43.

Research resource: modulators of glucocorticoid receptor activity identified by a new high-throughput screening assay.

Blackford JA Jr, Brimacombe KR, Dougherty EJ, Pradhan M, Shen M, Li Z, Auld DS, Chow CC, Austin CP, Simons SS Jr.

Mol Endocrinol. 2014 Jul;28(7):1194-206. doi: 10.1210/me.2014-1069. Epub 2014 May 21.

44.

Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects.

Hoskins JW, Ofori LO, Chen CZ, Kumar A, Sobczak K, Nakamori M, Southall N, Patnaik S, Marugan JJ, Zheng W, Austin CP, Disney MD, Miller BL, Thornton CA.

Nucleic Acids Res. 2014 Jun;42(10):6591-602. doi: 10.1093/nar/gku275. Epub 2014 May 5.

45.

A high throughput screening assay system for the identification of small molecule inhibitors of gsp.

Bhattacharyya N, Hu X, Chen CZ, Mathews Griner LA, Zheng W, Inglese J, Austin CP, Marugan JJ, Southall N, Neumann S, Northup JK, Ferrer M, Collins MT.

PLoS One. 2014 Mar 25;9(3):e90766. doi: 10.1371/journal.pone.0090766. eCollection 2014.

46.

Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.

Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, Chauhan L, Rao R, Gunewardena S, Schorno K, Austin CP, Maddocks K, Byrd J, Melnick A, Huang P, Wiestner A, Bhalla KN.

Cancer Res. 2014 May 1;74(9):2520-32. doi: 10.1158/0008-5472.CAN-13-2033. Epub 2014 Mar 5.

47.

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.

Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, Goldlust IS, Yasgar A, McKnight C, Boxer MB, Duveau DY, Jiang JK, Michael S, Mierzwa T, Huang W, Walsh MJ, Mott BT, Patel P, Leister W, Maloney DJ, Leclair CA, Rai G, Jadhav A, Peyser BD, Austin CP, Martin SE, Simeonov A, Ferrer M, Staudt LM, Thomas CJ.

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2349-54. doi: 10.1073/pnas.1311846111. Epub 2014 Jan 27.

48.

Innovation in therapeutics development at the NCATS.

Colvis CM, Austin CP.

Neuropsychopharmacology. 2014 Jan;39(1):230-2. doi: 10.1038/npp.2013.247. No abstract available.

49.

Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.

Ottinger EA, Kao ML, Carrillo-Carrasco N, Yanjanin N, Shankar RK, Janssen M, Brewster M, Scott I, Xu X, Cradock J, Terse P, Dehdashti SJ, Marugan J, Zheng W, Portilla L, Hubbs A, Pavan WJ, Heiss J, Vite CH, Walkley SU, Ory DS, Silber SA, Porter FD, Austin CP, McKew JC.

Curr Top Med Chem. 2014;14(3):330-9. Review.

50.

A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology.

Trucco MM, Awad O, Wilky BA, Goldstein SD, Huang R, Walker RL, Shah P, Katuri V, Gul N, Zhu YJ, McCarthy EF, Paz-Priel I, Meltzer PS, Austin CP, Xia M, Loeb DM.

PLoS One. 2013 Nov 6;8(11):e79950. doi: 10.1371/journal.pone.0079950. eCollection 2013.

Supplemental Content

Loading ...
Support Center